Eplerenone Pharmacia

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Pharmacia Corp (formerly GD Searle & Co) is developing eplerenone, an aldosterone receptor antagonist, as a potential treatment for congestive heart failure and systemic hypertension. The compound has been registered for hypertension and Pharmacia plans to submit a supplemental NDA for congestive heart failure in the first half of 2003 based on positive results from a phase III clinical trial.

Original languageEnglish
Pages (from-to)316-322
Number of pages7
JournalCurrent Opinion in Investigational Drugs
Volume4
Issue number3
Publication statusPublished - 1 Mar 2003

Cite this

@article{c59998a5f9e444cd9feb127a0d2b3bae,
title = "Eplerenone Pharmacia",
abstract = "Pharmacia Corp (formerly GD Searle & Co) is developing eplerenone, an aldosterone receptor antagonist, as a potential treatment for congestive heart failure and systemic hypertension. The compound has been registered for hypertension and Pharmacia plans to submit a supplemental NDA for congestive heart failure in the first half of 2003 based on positive results from a phase III clinical trial.",
author = "Liew, {Danny Yearn-Hian} and Jennifer Martin and Henry Krum",
year = "2003",
month = "3",
day = "1",
language = "English",
volume = "4",
pages = "316--322",
journal = "Current Opinion in Investigational Drugs",
issn = "1472-4472",
publisher = "Thomson Reuters (Prous Science)",
number = "3",

}

Eplerenone Pharmacia. / Liew, Danny Yearn-Hian; Martin, Jennifer; Krum, Henry.

In: Current Opinion in Investigational Drugs, Vol. 4, No. 3, 01.03.2003, p. 316-322.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Eplerenone Pharmacia

AU - Liew, Danny Yearn-Hian

AU - Martin, Jennifer

AU - Krum, Henry

PY - 2003/3/1

Y1 - 2003/3/1

N2 - Pharmacia Corp (formerly GD Searle & Co) is developing eplerenone, an aldosterone receptor antagonist, as a potential treatment for congestive heart failure and systemic hypertension. The compound has been registered for hypertension and Pharmacia plans to submit a supplemental NDA for congestive heart failure in the first half of 2003 based on positive results from a phase III clinical trial.

AB - Pharmacia Corp (formerly GD Searle & Co) is developing eplerenone, an aldosterone receptor antagonist, as a potential treatment for congestive heart failure and systemic hypertension. The compound has been registered for hypertension and Pharmacia plans to submit a supplemental NDA for congestive heart failure in the first half of 2003 based on positive results from a phase III clinical trial.

UR - http://www.scopus.com/inward/record.url?scp=0038300037&partnerID=8YFLogxK

M3 - Review Article

VL - 4

SP - 316

EP - 322

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1472-4472

IS - 3

ER -